November 16-18, 2019
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study
American Heart Association (AHA) Scientific Session 2019
Philadelphia, Pennsylvania
October 15-19, 2019
AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia
AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia
American Society of Human Genetics (ASHG) 2019 Annual Meeting
Houston, Texas
September 16-20, 2019
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Barcelona, Spain
September 13-16, 2019
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Philadelphia, PA
American Diabetes Association 79th Scientific Sessions
San Francisco, CA
May 25-28, 2019
Beneficial effects of AT-001, an aldose reductase inhibitor, in rodent models of Diabetic Cardiomyopathy
European Society for Cardiology 6th World Congress on Acute Heart Failure
Athens, Greece
October 15-16, 2018
A Novel Investigational Treatment In Preclinical Development For Galactosemia
NORD Rare Summit 2018
Washington, D.C.